4D Molecular Therapeutics (FDMT) News Today → He cracked the code to crypto… (From Weiss Ratings) (Ad) Free FDMT Stock Alerts $25.58 -0.17 (-0.66%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 7:31 AM | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.07. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.44 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 26.75%.May 15 at 7:03 AM | marketbeat.comHC Wainwright Equities Analysts Boost Earnings Estimates for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2024 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research note issued to investors on Monday, May 13th. HC Wainwright analyst M. Caufield now expects tMay 15 at 3:38 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)May 14 at 9:38 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)May 13 at 8:20 AM | marketbeat.com4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday.May 11, 2024 | finance.yahoo.com4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)May 11, 2024 | finance.yahoo.comWe're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To GrowMay 10, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income ProjectionsMay 10, 2024 | investorplace.comFDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.com4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsMay 7, 2024 | finance.yahoo.com4DMT to Participate in Upcoming Investor ConferenceMay 3, 2024 | finance.yahoo.comEtsy stock falling on Q1 earnings miss, cites macro headwindsMay 1, 2024 | globenewswire.com4DMT Announces Presentations at ARVO 2024 Annual MeetingApril 29, 2024 | seekingalpha.com4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed EvolutionApril 23, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 2.9%4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 2.9%April 21, 2024 | investing.com4d Molecular Therapeutics exec sells $45k in stockApril 20, 2024 | insidertrades.comScott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockApril 19, 2024 | insidertrades.comInsider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of StockApril 19, 2024 | marketbeat.comVontobel Holding Ltd. Invests $2.89 Million in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Vontobel Holding Ltd. purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 142,510 shares of the company's stock, valued at approximatelyApril 18, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 1,750 Shares4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,750 shares of the company's stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the sale, the insider now directly owns 1,737 shares in the company, valued at $44,710.38. The transaction was disclosed in a filing with the SEC, which is available at this link.April 17, 2024 | msn.com4D Molecular Therapeutics (FDMT) Price Target Increased by 5.81% to 53.24April 17, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 2.3% 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 2.3%April 15, 2024 | marketbeat.comRoyal Bank of Canada Increases 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $40.00Royal Bank of Canada raised their price objective on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the company an "outperform" rating in a research note on Monday.April 15, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)April 15, 2024 | marketbeat.comShort Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Expands By 9.6%4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 9,320,000 shares, an increase of 9.6% from the March 15th total of 8,500,000 shares. Based on an average trading volume of 1,170,000 shares, the days-to-cover ratio is currently 8.0 days.April 15, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $26.354D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $26.35April 15, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by BarclaysBarclays assumed coverage on 4D Molecular Therapeutics in a research report on Monday. They set an "overweight" rating and a $45.00 target price on the stock.April 15, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Invests $966,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)DekaBank Deutsche Girozentrale purchased a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 46,000 shares of tApril 14, 2024 | marketbeat.comVanguard Group Inc. Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Vanguard Group Inc. cut its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,902,467 shares of the company's stock after selliApril 12, 2024 | investing.com4D Molecular Therapeutics Inc (FDMT)April 9, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 4.1%4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 4.1%April 4, 2024 | insidertrades.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $259,102.34 in StockApril 4, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 SharesApril 1, 2024 | marketbeat.comBMO Capital Markets Trims 4D Molecular Therapeutics (NASDAQ:FDMT) Target Price to $63.00BMO Capital Markets cut their price target on 4D Molecular Therapeutics from $70.00 to $63.00 and set an "outperform" rating for the company in a research note on Monday.April 1, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 7.5% on Insider Selling4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.5% After Insider SellingApril 1, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Raised to $58.00Jefferies Financial Group raised their price objective on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a "buy" rating in a research report on Monday.April 1, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have issued aMarch 31, 2024 | insidertrades.comScott Bizily Sells 5,833 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockMarch 29, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company SharesMarch 29, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 5,833 Shares4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $35.04, for a total transaction of $204,388.32. Following the transaction, the insider now directly owns 1,737 shares of the company's stock, valued at $60,864.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.March 29, 2024 | markets.businessinsider.comOptimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710March 28, 2024 | globenewswire.com4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisMarch 27, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Reaches New 1-Year High at $35.724D Molecular Therapeutics (NASDAQ:FDMT) Reaches New 12-Month High at $35.72March 9, 2024 | marketbeat.comTrexquant Investment LP Purchases Shares of 44,443 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Trexquant Investment LP purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 44,443 shares of the company's stock, valued at approximately $566March 7, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buMarch 4, 2024 | globenewswire.com4DMT to Participate in Upcoming Investor ConferencesMarch 2, 2024 | finance.yahoo.com4D Molecular Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 2, 2024 | finance.yahoo.com4D Molecular Therapeutics Inc Reports Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.com4DMT Reports Full Year 2023 Financial Results and Operational HighlightsFebruary 24, 2024 | msn.com4D Molecular Therapeutics (FDMT) Price Target Increased by 47.68% to 50.55 Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Amazon's betting big on this unknown AI company (Ad)Amazon's Betting Big on This Unknown AI Company Amazon has just made a stunning $144 million investment in one small AI company. Discover why this company FDMT Media Mentions By Week FDMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.550.55▲Average Medical News Sentiment FDMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼152▲FDMT Articles Average Week Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VIR News TARS News CGEM News NMRA News SRRK News ADMA News BCRX News AUTL News INBX News FUSN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
